EQS-News

Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO) - Seite 2

Obefazimod data to be presented:

Presentation Title	Session	Presenter	Presentation/ Session Number	Session Hall	Date and Time (CET)
Digital Oral Presentations
Efficacy and safety of obefazimod in UC patients at weeks 48 and 96 of an open-label maintenance study among clinical responders at week 8 of the Phase 2b induction trial	Session 2: Clinical trials 1	Prof. Séverine Vermeire, M.D., Ph.D.   Head of the IBD Center at the University Hospitals Leuven, Belgium, and principal investigator in Europe for the study programs conducted and ongoing with obefazimod in UC	EC24-1273 Digital Oral Presentation (DOP)-12	A7	Feb. 22, 2024 Presentation time: 5:57-6:03 p.m. Session time: 5:45-6:45 p.m.
Efficacy of once-daily, orally administered obefazimod in patients with moderately to severely active UC at weeks 8, 48, and 96 broken down by induction treatment dose	DOP Session 8: Clinical trials 3	Prof. Bruce E. Sands, M.D., M.S. Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, NY	EC24-1275 Digital Oral Presentation (DOP)-71	A12	Feb. 23, 2024 Presentation time: 6:22-6:28 p.m. Session time: 5:40-6:40 p.m.
Poster Presentations
Obefazimod and its active metabolites ABX-464-N-Glu act by stabilizing protein-protein interaction among key RNA biogenesis partners, CBC and ARS2	Guided Poster Session	Didier Scherrer, Ph.D.